Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 1 clinical study titled ‘A Phase 1 First-in-Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV 324 in Adults With Hepatocellular Cancer or Squamous Cell Non-Small Cell Lung Cancer.’ The study aims to assess adverse events and changes in disease activity when ABBV-324 is administered to adults with hepatocellular cancer (HCC) or squamous-cell non-small cell lung cancer (LUSC). This research is significant as HCC and lung cancer are among the leading causes of cancer-related deaths worldwide.
The intervention being tested is ABBV-324, an investigational drug administered intravenously, with the goal of treating HCC and LUSC. The study involves administering ABBV-324 either alone or in comparison with the oral drug lenvatinib.
The study design is interventional, with a randomized allocation and a sequential intervention model. There is no masking involved, and the primary purpose is treatment. The study is structured to include a dose escalation phase followed by a dose optimization phase.
The study began on February 28, 2025, with the last update submitted on August 27, 2025. These dates mark the initiation and the most recent update of the study, indicating its ongoing status and progress.
From a market perspective, the successful development of ABBV-324 could enhance AbbVie’s portfolio, potentially boosting its stock performance and investor confidence. Given the competitive landscape of cancer treatments, advancements in this study could position AbbVie favorably against its competitors.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.